{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:20:26Z","timestamp":1780413626197,"version":"3.54.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific research project of Jiangsu Provincial Health Commission","award":["Z2022062; Z2023008"],"award-info":[{"award-number":["Z2022062; Z2023008"]}]},{"name":"Basic research project of Yancheng Science and Technology Bureau","award":["YCBK2023035"],"award-info":[{"award-number":["YCBK2023035"]}]},{"name":"Jiangsu Health International Exchange Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02247-2","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:16:19Z","timestamp":1772100979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug delivery"],"prefix":"10.1186","volume":"28","author":[{"given":"Jinjin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2247_CR1","doi-asserted-by":"crossref","unstructured":"Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. Cancers (Basel). 2020; 12(4).","DOI":"10.3390\/cancers12040916"},{"key":"2247_CR2","doi-asserted-by":"publisher","first-page":"109692","DOI":"10.1016\/j.steroids.2025.109692","volume":"223","author":"M Tanio","year":"2025","unstructured":"Tanio M, Miyamoto Y, Saka T, Kudo Y, Hayashi R, Kawano S, et al. Kobochromone A, a polyphenol in Carex kobomugi, suppresses androgen signaling induced by 11-oxygenated androgens and enhances the efficacy of AKT inhibitors in triple-negative breast cancer cells. Steroids. 2025;223:109692.","journal-title":"Steroids"},{"key":"2247_CR3","doi-asserted-by":"crossref","unstructured":"Li J, Yao J. CD8(+) T cell\u2013related KCTD5 contributes to malignant progression and unfavorable clinical outcome of patients with triple\u2013negative breast cancer. Mol Med Rep. 2024; 30(3).","DOI":"10.3892\/mmr.2024.13290"},{"key":"2247_CR4","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.pharmthera.2022.108253","volume":"237","author":"JY So","year":"2022","unstructured":"So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237:108253.","journal-title":"Pharmacol Ther"},{"key":"2247_CR5","doi-asserted-by":"publisher","first-page":"1441667","DOI":"10.3389\/fimmu.2024.1441667","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Li H, Yang W, Shi Y. Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment. Front Immunol. 2024;15:1441667.","journal-title":"Front Immunol"},{"issue":"4","key":"2247_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479\u201389.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2247_CR7","doi-asserted-by":"publisher","first-page":"2246720","DOI":"10.1080\/13510002.2023.2246720","volume":"28","author":"N Xu","year":"2023","unstructured":"Xu N, Liu S, Zhang Y, Chen Y, Zuo Y, Tan X, et al. Oxidative stress signaling in the pathogenesis of diabetic cardiomyopathy and the potential therapeutic role of antioxidant naringenin. Redox Rep. 2023;28(1):2246720.","journal-title":"Redox Rep"},{"issue":"1","key":"2247_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","journal-title":"Mol Cancer"},{"issue":"2","key":"2247_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2247_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won KA, Spruck C. Triple\u2013negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245\u201361.","journal-title":"Int J Oncol"},{"issue":"1","key":"2247_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16(1):100.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2247_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","volume":"18","author":"Y Xue","year":"2021","unstructured":"Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, et al. Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021;18(2):187\u2013203.","journal-title":"Expert Opin Drug Deliv"},{"key":"2247_CR13","doi-asserted-by":"crossref","unstructured":"Arzi L, Mollaei H, Hoshyar R. Countering triple negative breast cancer via impeding Wnt\/\u03b2-Catenin signaling, a phytotherapeutic approach. Plants (Basel). 2022; 11(17).","DOI":"10.3390\/plants11172191"},{"issue":"12","key":"2247_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12032-022-01782-0","volume":"39","author":"K Kawaguchi","year":"2022","unstructured":"Kawaguchi K, Maeshima Y, Toi M. Tumor immune microenvironment and systemic response in breast cancer. Med Oncol. 2022;39(12):208.","journal-title":"Med Oncol"},{"key":"2247_CR15","doi-asserted-by":"publisher","first-page":"115514","DOI":"10.1016\/j.biopha.2023.115514","volume":"167","author":"M Chen","year":"2023","unstructured":"Chen M, Bie L, Ying J. Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy. Biomed Pharmacother. 2023;167:115514.","journal-title":"Biomed Pharmacother"},{"key":"2247_CR16","doi-asserted-by":"publisher","first-page":"674192","DOI":"10.3389\/fimmu.2021.674192","volume":"12","author":"J Goldberg","year":"2021","unstructured":"Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, et al. The immunology of hormone receptor positive breast cancer. Front Immunol. 2021;12:674192.","journal-title":"Front Immunol"},{"key":"2247_CR17","doi-asserted-by":"publisher","first-page":"1061789","DOI":"10.3389\/fonc.2022.1061789","volume":"12","author":"A Schreier","year":"2022","unstructured":"Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E. Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. Front Oncol. 2022;12:1061789.","journal-title":"Front Oncol"},{"issue":"4","key":"2247_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"35","key":"2247_CR19","doi-asserted-by":"publisher","first-page":"e202300379","DOI":"10.1002\/anie.202300379","volume":"62","author":"F Zeng","year":"2023","unstructured":"Zeng F, Nijiati S, Tang L, Ye J, Zhou Z, Chen X. Ferroptosis detection: from approaches to applications. Angew Chem Int Ed Engl. 2023;62(35):e202300379.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"12","key":"2247_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","volume":"33","author":"LE Pope","year":"2023","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 2023;33(12):1077\u201387.","journal-title":"Trends Cell Biol"},{"issue":"6","key":"2247_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25(6):424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2247_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273\u201385.","journal-title":"Cell"},{"issue":"11\u201312","key":"2247_CR23","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","volume":"73","author":"JY Cao","year":"2016","unstructured":"Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73(11\u201312):2195\u2013209.","journal-title":"Cell Mol Life Sci"},{"key":"2247_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","volume":"152","author":"F Ursini","year":"2020","unstructured":"Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic Biol Med. 2020;152:175\u201385.","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"2247_CR25","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054\u201381.","journal-title":"Autophagy"},{"key":"2247_CR26","doi-asserted-by":"crossref","unstructured":"Jiang Y, Glandorff C, Sun M. GSH and Ferroptosis: side-by-side partners in the fight against tumors. Antioxid (Basel). 2024; 13(6).","DOI":"10.3390\/antiox13060697"},{"key":"2247_CR27","doi-asserted-by":"publisher","first-page":"104919","DOI":"10.1016\/j.phrs.2020.104919","volume":"159","author":"Y Qiu","year":"2020","unstructured":"Qiu Y, Cao Y, Cao W, Jia Y, Lu N. The application of ferroptosis in diseases. Pharmacol Res. 2020;159:104919.","journal-title":"Pharmacol Res"},{"issue":"4","key":"2247_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513\u201334.","journal-title":"Cancer Cell"},{"issue":"10","key":"2247_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cac2.12487","volume":"43","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Sun L, Guo J, Ma J. The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy. Cancer Commun (Lond). 2023;43(10):1071\u201396.","journal-title":"Cancer Commun (Lond)"},{"issue":"8","key":"2247_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lu S, Wu LL, Yang L, Yang L, Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 2023;14(8):519.","journal-title":"Cell Death Dis"},{"key":"2247_CR31","doi-asserted-by":"publisher","first-page":"rbad004","DOI":"10.1093\/rb\/rbad004","volume":"10","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zhao Y, Zhou H, Chen C. Ferroptosis: challenges and opportunities for nanomaterials in cancer therapy. Regen Biomater. 2023;10:rbad004.","journal-title":"Regen Biomater"},{"key":"2247_CR32","doi-asserted-by":"publisher","first-page":"1650219","DOI":"10.3389\/fonc.2025.1650219","volume":"15","author":"W Gao","year":"2025","unstructured":"Gao W, Tan J, Yu C. Ferroptosis in the tumor microenvironment: mechanisms, advances, and therapeutic perspectives. Front Oncol. 2025;15:1650219.","journal-title":"Front Oncol"},{"key":"2247_CR33","doi-asserted-by":"crossref","unstructured":"Xu H, Lu Y, Zeng Q, Zhu X, Guan W, Liu S. Ferroptosis of immune cells in infection, inflammation and tumor progression. Biomolecules. 2025; 15(10).","DOI":"10.3390\/biom15101464"},{"issue":"7","key":"2247_CR34","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/0008-5472.CAN-23-4042","volume":"84","author":"G Lei","year":"2024","unstructured":"Lei G, Gan B. Exploring ferroptosis-inducing therapies for cancer treatment: challenges and opportunities. Cancer Res. 2024;84(7):961\u20134.","journal-title":"Cancer Res"},{"issue":"6","key":"2247_CR35","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/med.21971","volume":"43","author":"M Ashrafizadeh","year":"2023","unstructured":"Ashrafizadeh M, Zarrabi A, Bigham A, Taheriazam A, Saghari Y, Mirzaei S, et al. (Nano)platforms in breast cancer therapy: drug\/gene delivery, advanced nanocarriers and immunotherapy. Med Res Rev. 2023;43(6):2115\u201376.","journal-title":"Med Res Rev"},{"issue":"1","key":"2247_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17(1):16.","journal-title":"J Hematol Oncol"},{"issue":"47","key":"2247_CR37","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.1039\/D5NR03627E","volume":"17","author":"Y Tang","year":"2025","unstructured":"Tang Y, Zhou Q, Fan Y, Liu TM, Zhu L, Liu M. Nanomaterial-mediated ferroptosis as a promising strategy for cancer therapy. Nanoscale. 2025;17(47):27066\u201384.","journal-title":"Nanoscale"},{"issue":"1","key":"2247_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12935-024-03610-z","volume":"25","author":"H Azimizonuzi","year":"2025","unstructured":"Azimizonuzi H, Ghayourvahdat A, Ahmed MH, Kareem RA, Zrzor AJ, Mansoor AS, et al. A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis. Cancer Cell Int. 2025;25(1):26.","journal-title":"Cancer Cell Int"},{"key":"2247_CR39","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2147\/IJN.S492713","volume":"20","author":"LJ Guo","year":"2025","unstructured":"Guo LJ, Wu J, Lu W, Li J, Wang Y, Yang H, et al. Nanoparticles modulating the immune microenvironment in breast cancer treatment. Int J Nanomed. 2025;20:1367\u201382.","journal-title":"Int J Nanomed"},{"issue":"17","key":"2247_CR40","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.7150\/thno.49577","volume":"10","author":"Y Shi","year":"2020","unstructured":"Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921\u20134.","journal-title":"Theranostics"},{"key":"2247_CR41","doi-asserted-by":"crossref","unstructured":"Wu Q, Yao X, Duan X, Chen X, Zhang J. Nanomedicine reimagined: translational strategies for precision tumor theranostics. Adv Mater. 2025:e10293.","DOI":"10.1002\/adma.202510293"},{"issue":"11","key":"2247_CR42","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/17435889.2025.2476377","volume":"20","author":"F Yuan","year":"2025","unstructured":"Yuan F, Li ZD, Li Q, Zeng Y, Zhang G, Li Y. Designing nanoparticles to minimize unintended inflammatory responses: a step toward safer and more effective precision nanomedicine. Nanomed (Lond). 2025;20(11):1213\u20137.","journal-title":"Nanomed (Lond)"},{"issue":"49","key":"2247_CR43","doi-asserted-by":"publisher","first-page":"13415","DOI":"10.1021\/acs.jpcb.1c08609","volume":"125","author":"N Narayanan","year":"2021","unstructured":"Narayanan N, Kim JH, Santhakumar H, Joseph MM, Karunakaran V, Shamjith S, et al. Nanotheranostic probe built on methylene blue loaded cucurbituril [8] and gold nanorod: targeted phototherapy in combination with SERS imaging on breast cancer cells. J Phys Chem B. 2021;125(49):13415\u201324.","journal-title":"J Phys Chem B"},{"issue":"11","key":"2247_CR44","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"issue":"14","key":"2247_CR45","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.7150\/thno.57803","volume":"11","author":"CH Hsieh","year":"2021","unstructured":"Hsieh CH, Hsieh HC, Shih FS, Wang PW, Yang LX, Shieh DB, et al. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Theranostics. 2021;11(14):7072\u201391.","journal-title":"Theranostics"},{"key":"2247_CR46","doi-asserted-by":"publisher","first-page":"100457","DOI":"10.1016\/j.mtbio.2022.100457","volume":"17","author":"C Bae","year":"2022","unstructured":"Bae C, Kim H, Kook YM, Lee C, Kim C, Yang C, et al. Induction of ferroptosis using functionalized iron-based nanoparticles for anti-cancer therapy. Mater Today Biol. 2022;17:100457.","journal-title":"Mater Today Bio"},{"issue":"44","key":"2247_CR47","doi-asserted-by":"publisher","first-page":"24153","DOI":"10.1021\/jacs.3c08032","volume":"145","author":"Q Feng","year":"2023","unstructured":"Feng Q, Fang W, Guo Y, Hu P, Shi J. Nebulized therapy of early orthotopic lung cancer by iron-based nanoparticles: macrophage-regulated ferroptosis of cancer stem cells. J Am Chem Soc. 2023;145(44):24153\u201365.","journal-title":"J Am Chem Soc"},{"issue":"20","key":"2247_CR48","doi-asserted-by":"publisher","first-page":"e2306766","DOI":"10.1002\/smll.202306766","volume":"20","author":"Q Wu","year":"2024","unstructured":"Wu Q, Li Z, Zhou X, Wei Z, Ramadan S, Xu Y, et al. Photothermal ferrotherapy - induced immunogenic cell death via iron-based ternary chalcogenide nanoparticles against triple-negative breast cancer. Small. 2024;20(20):e2306766.","journal-title":"Small"},{"issue":"5","key":"2247_CR49","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.7150\/ijbs.77979","volume":"19","author":"C Zhou","year":"2023","unstructured":"Zhou C, Yu T, Zhu R, Lu J, Ouyang X, Zhang Z, et al. Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation. Int J Biol Sci. 2023;19(5):1471\u201389.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"2247_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41419-022-05082-3","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang W, Gong M, Zhang W, Mo J, Zhang S, Zhu Z, et al. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3\/GPX4 signalling. Cell Death Dis. 2022;13(7):630.","journal-title":"Cell Death Dis"},{"issue":"22","key":"2247_CR51","doi-asserted-by":"publisher","first-page":"24866","DOI":"10.18632\/aging.203721","volume":"13","author":"L Gao","year":"2021","unstructured":"Gao L, Xue J, Liu X, Cao L, Wang R, Lei L. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. Aging. 2021;13(22):24866\u201381.","journal-title":"Aging"},{"issue":"9","key":"2247_CR52","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/gutjnl-2022-327909","volume":"72","author":"C Conche","year":"2023","unstructured":"Conche C, Finkelmeier F, Pe\u0161i\u0107 M, Nicolas AM, B\u00f6ttger TW, Kennel KB, et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023;72(9):1774\u201382.","journal-title":"Gut"},{"issue":"720","key":"2247_CR53","doi-asserted-by":"publisher","first-page":"eadg3049","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049.","journal-title":"Sci Transl Med"},{"issue":"7939","key":"2247_CR54","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","volume":"612","author":"R Kim","year":"2022","unstructured":"Kim R, Hashimoto A, Markosyan N, Tyurin VA, Tyurina YY, Kar G, et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022;612(7939):338\u201346.","journal-title":"Nature"},{"key":"2247_CR55","doi-asserted-by":"publisher","first-page":"102463","DOI":"10.1016\/j.redox.2022.102463","volume":"56","author":"X Hao","year":"2022","unstructured":"Hao X, Zheng Z, Liu H, Zhang Y, Kang J, Kong X, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463.","journal-title":"Redox Biol"},{"issue":"1","key":"2247_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12951-023-02146-0","volume":"21","author":"S Wang","year":"2023","unstructured":"Wang S, Guo Q, Xu R, Lin P, Deng G, Xia X. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma. J Nanobiotechnol. 2023;21(1):383.","journal-title":"J Nanobiotechnol"},{"issue":"9\u201310","key":"2247_CR57","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s10495-023-01868-8","volume":"28","author":"Y Shi","year":"2023","unstructured":"Shi Y, Wang Y, Dong H, Niu K, Zhang W, Feng K, et al. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy. Apoptosis. 2023;28(9\u201310):1423\u201335.","journal-title":"Apoptosis"},{"issue":"Pt 2","key":"2247_CR58","doi-asserted-by":"publisher","first-page":"134777","DOI":"10.1016\/j.ijbiomac.2024.134777","volume":"278","author":"MD Caverzan","year":"2024","unstructured":"Caverzan MD, Ibarra LE. Advancing glioblastoma treatment through iron metabolism: a focus on TfR1 and Ferroptosis innovations. Int J Biol Macromol. 2024;278(Pt 2):134777.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"2247_CR59","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1021\/acs.molpharmaceut.7b01103","volume":"15","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Zhao X, Cheng Y, Guo X, Yuan W. Iron oxide nanoparticles-based vaccine delivery for cancer treatment. Mol Pharm. 2018;15(5):1791\u20139.","journal-title":"Mol Pharm"},{"key":"2247_CR60","doi-asserted-by":"crossref","unstructured":"Liu CC, Li HH, Lin JH, Chiang MC, Hsu TW, Li AF et al. Esophageal Cancer Stem-like Cells Resist Ferroptosis-Induced Cell Death by Active Hsp27-GPX4 Pathway. Biomolecules. 2021; 12(1).","DOI":"10.3390\/biom12010048"},{"issue":"1","key":"2247_CR61","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki B, Maschalidi S, Pinney J, Adjemian S, Vanden Berghe T, Ravichandran KS, et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat Commun. 2022;13(1):3676.","journal-title":"Nat Commun"},{"issue":"2","key":"2247_CR62","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/jacs.1c09753","volume":"144","author":"L Xie","year":"2022","unstructured":"Xie L, Li J, Wang G, Sang W, Xu M, Li W, et al. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy. J Am Chem Soc. 2022;144(2):787\u201397.","journal-title":"J Am Chem Soc"},{"issue":"12","key":"2247_CR63","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994\u20133006.","journal-title":"Mol Oncol"},{"issue":"7","key":"2247_CR64","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mc.23183","volume":"59","author":"H Ruan","year":"2020","unstructured":"Ruan H, Leibowitz BJ, Zhang L, Yu J. Immunogenic cell death in colon cancer prevention and therapy. Mol Carcinog. 2020;59(7):783\u201393.","journal-title":"Mol Carcinog"},{"issue":"5","key":"2247_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","volume":"24","author":"P Meier","year":"2024","unstructured":"Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24(5):299\u2013315.","journal-title":"Nat Rev Cancer"},{"issue":"Pt 3","key":"2247_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.semcancer.2022.03.009","volume":"86","author":"X Niu","year":"2022","unstructured":"Niu X, Chen L, Li Y, Hu Z, He F. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC. Semin Cancer Biol. 2022;86(Pt 3):273\u201385.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2247_CR67","doi-asserted-by":"publisher","first-page":"e2309562","DOI":"10.1002\/adma.202309562","volume":"36","author":"J Liu","year":"2024","unstructured":"Liu J, Zhan J, Zhang Y, Huang L, Yang J, Feng J, et al. Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and cancer immunotherapy. Adv Mater. 2024;36(9):e2309562.","journal-title":"Adv Mater"},{"issue":"1","key":"2247_CR68","first-page":"56","volume":"18","author":"X Wei","year":"2025","unstructured":"Wei X, Jiang Y, Chenwu F, Li Z, Wan J, Li Z, et al. Synergistic ferroptosis-immunotherapy nanoplatforms: multidimensional engineering for tumor microenvironment remodeling and therapeutic optimization. Nanomicro Lett. 2025;18(1):56.","journal-title":"Nanomicro Lett"},{"issue":"11","key":"2247_CR69","doi-asserted-by":"publisher","first-page":"114868","DOI":"10.1016\/j.celrep.2024.114868","volume":"43","author":"K Xiao","year":"2024","unstructured":"Xiao K, Zhang S, Peng Q, Du Y, Yao X, Ng II, et al. PD-L1 protects tumor-associated dendritic cells from ferroptosis during immunogenic chemotherapy. Cell Rep. 2024;43(11):114868.","journal-title":"Cell Rep"},{"key":"2247_CR70","doi-asserted-by":"crossref","unstructured":"Coradduzza D, Congiargiu A, Chen Z, Zinellu A, Carru C, Medici S. Ferroptosis and senescence: a systematic review. Int J Mol Sci. 2023; 24(4).","DOI":"10.3390\/ijms24043658"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02247-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:03:39Z","timestamp":1775037819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02247-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2247"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02247-2","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Ethics Committee of the First People\u2019s Hospital of Yancheng City (Approval No. XIUCC-2022-849) and conducted in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"68"}}